STOCK TITAN

Inhibrx Inc - INBX STOCK NEWS

Welcome to our dedicated news page for Inhibrx (Ticker: INBX), a resource for investors and traders seeking the latest updates and insights on Inhibrx.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Inhibrx's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Inhibrx's position in the market.

Rhea-AI Summary
Inhibrx, Inc. reported financial results for Q4 and FY 2023, including the sale of INBRX-101 to Sanofi, termination of INBRX-105 program, and a company-wide blackout. Cash and cash equivalents decreased to $277.9 million. R&D expenses and G&A expenses increased due to various factors. Net loss was $93.6 million in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.47%
Tags
-
Rhea-AI Summary
Inhibrx, Inc. (Nasdaq: INBX) and Sanofi (Nasdaq: SNY) have entered into a definitive agreement under which Sanofi will acquire all assets and liabilities associated with INBRX-101. Inhibrx shareholders will receive $30 per share in cash, a CVR of $5, and 0.25 shares in New Inhibrx. Sanofi will pay off Inhibrx's outstanding debt and capitalize New Inhibrx with $200 million in cash.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.91%
Tags
none
-
Rhea-AI Summary
Inhibrx, Inc. (Nasdaq: INBX) reported financial results for Q3 2023, including a $200 million private placement financing. They also announced retaining rights to INBRX-101 and shared positive preliminary efficacy and safety data from the Phase 1 trial of INBRX-109 at the CTOS Conference. Cash and cash equivalents increased to $337.3 million, with a net loss of $51.8 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.37%
Tags
Rhea-AI Summary
Inhibrx, Inc. announced preliminary efficacy and safety data from the Phase 1 trial of INBRX-109 in combination with Irinotecan and Temozolomide (IRI/TMZ) for the treatment of advanced or metastatic, unresectable Ewing sarcoma. The disease control rate was 76.9%, with 7 patients achieving partial responses. Durable clinical benefit was observed in 30.8% of patients. The most common adverse events were diarrhea, nausea, and fatigue. No grade 3 or higher liver-related events occurred.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.46%
Tags
-
Rhea-AI Summary
Inhibrx, Inc. to present at upcoming scientific conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.81%
Tags
conferences
-
Rhea-AI Summary
Chiesi declines option for ex-North American rights to develop INBRX-101 for AATD, Inhibrx now has full global rights. Potential opportunity in Europe and Japan for GvHD indication.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.78%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.96%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.69%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.53%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.15%
Tags
none
Inhibrx Inc

Nasdaq:INBX

INBX Rankings

INBX Stock Data

1.66B
21.98M
19.57%
86.53%
4.54%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
La Jolla

About INBX

development of antibodies